1. Introduction {#sec1}
===============

In a recent overview from Bray et al., prostate cancer is the most common cancer in males in the majority of countries in the world \[[@B1]\]. The clinical course is highly variable, and active surveillance and watchful waiting are newer concepts in the therapy of prostate cancer \[[@B2]\]. Therefore, we need reliable criteria for the distinction between high-risk and low-risk patients. It is hoped that molecular prognostic markers will improve this selection.

Protein phosphatase 1 nuclear-targeting subunit (PNUTS) is a bifunctional gene encoding both the PNUTS protein and, by alternative splicing, a long noncoding RNA termed lncRNA-PNUTS \[[@B3]\]. The PNUTS protein is ubiquitously expressed and associates with protein phosphatase 1 (PP1) to control its activity \[[@B4]\]. PP1 is one of the major human protein phosphatases that dephosphorylate hundreds of kinases involved in a wide range of cellular actions \[[@B5]\]. Accordingly, PNUTS is implicated in all PP1-governed processes including RNA processing \[[@B6]\], DNA repair \[[@B7]\], chromatin decondensation \[[@B8]\], and maintenance of telomere stability \[[@B9]\]. PP1 is also involved in growth control through interaction with PTEN, RB1, MYC, and Aurora kinases \[[@B10]--[@B14]\]. The noncoding transcript lncRNA-PNUTS appears to function as a regulator of epithelial-mesenchymal transition, an essential process for tissue and organ formation, and also for tumor development and metastasis \[[@B15]\]. Several studies suggest that targeting PNUTS may have antitumor activity. For example, PNUTS knockdown increased apoptosis in breast, ovarian, and colon cancers cells \[[@B11]\] and potentiated the apoptotic effect of the cyclin-dependent kinase inhibitor roscovitine in breast and colon cancer cells \[[@B16]\]. Injection of the microRNA miR-34a, a natural downregulator of PNUTS, into glioblastoma xenograft tumors reduced telomere length \[[@B17]\] and targeting PNUTS with miR-383 induced cell cycle arrest in testicular embryonal carcinoma cells \[[@B18]\]. Most recently, it was shown that PNUTS is an essential partner of poly (ADP-ribose) polymerase 1 in DNA repair \[[@B19]\], making PNUTS a potential drug target in the therapy of DNA double-strand repair-deficient tumors.

One report using mRNA expression data from the Oncomine database \[[@B20]\] suggests that PNUTS may be upregulated in prostate cancers as compared to normal prostate tissues \[[@B10]\]. This observation prompted us to further investigate the role of this potentially important gene by analyzing a prostate cancer tissue microarray containing tumor samples from more than 17,000 individual patients.

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

The 17,747 patients had prostatectomy between 1992 and 2015 (Department of Urology and the Martini Clinic at the University Medical Center Hamburg-Eppendorf). Quantitative Gleason grading was performed as described \[[@B21]\]. Follow-up data were available for 14,667 patients with a median follow-up of 48 months. Prostate-specific antigen (PSA) recurrence was defined as the time point when postoperative PSA was at least 0.2 ng/ml and increasing at subsequent measurements. Patient characteristics are summarized in [Table 1](#tab1){ref-type="table"}. The tissue microarray (TMA) manufacturing process was described earlier \[[@B22]\]. A single 0.6 mm core was taken for each patient. The TMA was annotated with data on Ki67 labeling index (Ki67LI) \[[@B23]\], ERG protein expression and ERG rearrangement analysis by fluorescence in situ hybridization (FISH) \[[@B24]\], and deletion status of 3p13 (FOXP1) \[[@B25]\], 5q21 (CHD1) \[[@B26]\], 6q15 (MAP3K7) \[[@B27]\], 8p21 \[[@B28]\], 10q23 (PTEN) \[[@B29]\], 12p13 \[[@B30]\], 12q24 \[[@B31]\], 13q14 \[[@B32]\], 16q24 \[[@B33]\], 17p13 \[[@B34]\], and 18q21 \[[@B35]\]. The usage of archived diagnostic leftover tissues for manufacturing of tissue microarrays and their analysis for research purposes as well as patient data analysis has been approved by local laws (HmbKHG, §12a) and by the local ethics committee (Ethics Commission Hamburg, WF-049/09). All work has been carried out in compliance with the Helsinki Declaration.

2.2. Immunohistochemistry {#sec2.2}
-------------------------

Freshly cut TMA sections were stained in a single experiment, deparaffinized, and exposed to heat-induced antigen retrieval (5 min, 121°C, pH 7.8 Tris-EDTA buffer). Primary antibody specific for PNUTS (rabbit polyclonal antibody, Novus Biologicals, Centennial, Colorado, USA, NB100-604; dilution 1 : 4,050) was applied (37°C, 60 min) and visualized with EnVision (Dako, Glostrup, Denmark). Anti-PNUTS showed punctuate staining inside the nuclei that was typically accompanied by weaker cytoplasmic costaining. Because the nuclear staining pattern is compatible with its function and cellular localization \[[@B36]\], only nuclear staining was scored as follows. The staining intensity (0, 1+, 2+, and 3+) as well as the fraction (percentage) of stained cells was recorded for each tissue spot. A final score was built from these two parameters as follows. Lack of any staining (intensity 0) was considered "negative," 1+ staining in ≤70% of tumor cells or 2+ staining in ≤30% of tumor cells was considered "weak," 2+ staining in \>70% of tumor cells or 2+ staining in \>30% but ≤70% of tumor cells or 3+ staining in ≤30% of tumor cells was considered "moderate," and 2+ staining in \>70% of tumor cells or 3+ staining in \>30% of tumor cells was considered "strong."

2.3. Statistics {#sec2.3}
---------------

JMP 12 software (SAS Institute Inc., NC, USA) was used for calculations. Contingency tables and the *χ*^2^ test were utilized to examine associations between molecular and histopathological tumor parameters. Kaplan-Meier survival curves were analyzed with the log-rank test to detect differences between groups. Cox proportional hazards regression analysis was performed to test for statistical independence between pathological, molecular, and clinical variables.

3. Results {#sec3}
==========

3.1. Technical Issues {#sec3.1}
---------------------

A total of 12,235 of 17,747 tumor samples (69%) were interpretable in our TMA analysis. Reasons for 31% noninformative cases included lack of tissue samples or absence of unequivocal cancer tissue in the TMA spot.

3.2. PNUTS Expression in Normal and Cancerous Prostate Tissues {#sec3.2}
--------------------------------------------------------------

PNUTS staining was predominantly nuclear with a focus on nucleoli resulting in a "punctuated" staining pattern. In 20 cases of normal prostate gland, luminal cells stained weakly positive for PNUTS, while basal cells were negative ([Figure 1(a1)](#fig1){ref-type="fig"}). In prostate cancers, nuclear staining was seen in 9632 of our 12,235 (78.7%) interpretable tumors and was considered weak in 33.9%, moderate in 34.7%, and strong in 10.1% of cases (Figures [1(a2)](#fig1){ref-type="fig"}, [1(b)](#fig1){ref-type="fig"}, and [1(e)](#fig1){ref-type="fig"}). Increased PNUTS staining showed significant associations with adverse tumor features ([Table 2](#tab2){ref-type="table"}). Strong staining of PNUTS was associated with advanced tumor stage (*p* \< 0.0001), high classical and quantitative Gleason grade (*p* \< 0.0001 each), presence of lymph node metastasis (*p* \< 0.0001), high preoperative PSA level (*p* = 0.0001), and positive surgical margin (*p* \< 0.0001). PNUTS staining was also linked to early biochemical recurrence ([Figure 2](#fig2){ref-type="fig"}). Accordingly, subgroup analyses of cancers with identical Gleason score revealed a prognostic role of PNUTS expression in Gleason 3+4 (*p* \< 0.0001) and Gleason 4+3 (*p* = 0.0002, Supplementary Figure [S2a](#supplementary-material-1){ref-type="supplementary-material"}) as well as in particular quantitative Gleason grades (Supplementary Figure [S2d, h](#supplementary-material-1){ref-type="supplementary-material"}).

3.3. PNUTS and *TMPRSS2:ERG* Fusion Status {#sec3.3}
------------------------------------------

Data on both ERG FISH and IHC were available in 4,998 cancers with concordant results in 95% of cases. PNUTS staining was significantly more prevalent in cancers harboring *TMPRSS2:ERG* rearrangements than in cancer lacking ERG fusions ([Figure 3](#fig3){ref-type="fig"}). Because of these differences, associations of PNUTS with tumor phenotype and PSA recurrence were separately analyzed in ERG-negative and ERG-positive cancers. All these associations with tumor phenotype (Supplementary Tables [S1 and S2](#supplementary-material-1){ref-type="supplementary-material"}) and clinical outcome (*p* \< 0.0001 each, Supplementary Figure [S1](#supplementary-material-1){ref-type="supplementary-material"}) hold true in both subgroups.

3.4. PNUTS and Chromosomal Deletions {#sec3.4}
------------------------------------

For 10 of 11 analyzed deletions, PNUTS staining was stronger in deleted than in nondeleted cancers. This difference reached statistical significance for 8 of the 11 analyzed regions (Supplementary Figure [S1](#supplementary-material-1){ref-type="supplementary-material"}). In ERG-negative cancers, a statistically significant difference was also seen for 8 of 11 analyzed deletions (Supplementary Figure [S1b](#supplementary-material-1){ref-type="supplementary-material"}). In ERG-positive cancers, a statistically significant difference was found for 5 of 11 deletions (Supplementary Figure [S1c](#supplementary-material-1){ref-type="supplementary-material"}). A particularly prominent PNUTS staining was seen in cancers with PTEN (10q23) and 12p deletions, which was highly significant in all, ERG-negative, and ERG-positive cancers (*p* \< 0.0001 each).

3.5. PNUTS, Androgen Receptor, and Tumor Cell Proliferation (Ki67LI) {#sec3.5}
--------------------------------------------------------------------

In 5,414 cancers with available AR expression data, the intensity of PNUTS staining was highly related to AR levels ([Figure 4](#fig4){ref-type="fig"}). This also applied for subsets of ERG-negative and ERG-positive cancers (data not shown). PNUTS staining was significantly linked to increased Ki67LI ([Table 3](#tab3){ref-type="table"}). This held true in most subsets of cancers with identical Gleason score, including Gleason ≤3+3 (*p* \< 0.0001), 3+4 (*p* \< 0.0001), 3+4 with tertiary grade 5 (*p* = 0.0019), and 4+3 (*p* = 0.0009).

3.6. PSA Recurrence-Free Survival in Uni- and Multivariable Analyses {#sec3.6}
--------------------------------------------------------------------

The univariable analysis showed a moderate Cox proportional hazard ratio of 2.21 for strong versus negative PNUTS expression compared with a hazard ratio of 5.91 for Gleason grading ([Table 4](#tab4){ref-type="table"}). When the five variables of the univariable analysis were combined in the multivariable model, the hazard ratios were reduced but remained significant for each variable indicating that they are in part independent of each other. Strong PNUTS expression was predictive at a comparable level as PTEN deletion. The effect was observed in both ERG subsets ([Table 4](#tab4){ref-type="table"}, Supplementary Table [S3](#supplementary-material-1){ref-type="supplementary-material"}).

4. Discussion {#sec4}
=============

The results of our study identify high PNUTS protein expression as a predictor of poor prognosis in prostate cancer. The peculiar "punctuated" nuclear staining pattern of PNUTS has already been described in an earlier study \[[@B36]\]. It fits well with the known interaction with PP1, which constitutes an important part of the nucleolar proteome. The PP1 subunit PP1 gamma and to a lesser extent PP1 beta are highly concentrated in the nucleoli of interphase cells \[[@B36]\]. Finding PNUTS expression at higher levels in cancer glands as compared to adjacent normal prostate gland suggests that the protein becomes upregulated during prostate cancer development and progression. Our findings are supported by findings from the Oncomine database, where PNUTS mRNA levels were higher in prostate cancers as compared to normal prostate tissues \[[@B10]\]. Additional expression data from the same database revealed PNUTS mRNA upregulation also in other tumor-normal pairs, including skin, kidney, and brain tissues. An immunohistochemical study also demonstrated PNUTS upregulation in esophageal carcinomas \[[@B10]\]. Altogether, these data suggest that PNUTS upregulation may accompany neoplastic transformation in many tumor types.

The association of high PNUTS staining with adverse tumor features, including advanced stage, high Gleason grade, nodal metastases, and early biochemical recurrence, argues for a role of PNUTS overexpression in prostate cancer progression. PNUTS is a protein that has not been extensively studied in cancer. A Medline search on 9^th^ March 2019 using the terms PNUTS and CANCER resulted in 19 citations. Data on a potential prognostic role of PNUTS activity in other cancer types is thus largely lacking. Kavela et al. reported that immunohistochemical PNUTS expression was stronger in 20 cases of triple-positive breast cancers that in 20 triple-negative breast cancers \[[@B10]\]. Overall, the known interaction with key genes in cancer including PTEN and PP1 regulating also RB1, MYC, MDM2, p53, and Aurora kinases is consistent with an important role of PNUTS in cancer \[[@B13], [@B37]--[@B40]\].

Further of note, PNUTS maps to chromosome 6p21.3 within the major histocompatibility complex (MHC) class I gene cluster and contains binding intervals for the MHC master regulator CIITA \[[@B41]\]. It cannot be excluded that PNUTS overexpression may also impact antigen presentation and lead to altered immune responses against cancer.

The highly annotated molecular database enabled us to compare PNUTS expression with other relevant molecular alterations. About 50% of prostate cancers contain gene fusions connecting the androgen-regulated *TMPRSS2* gene with the transcription factor *ERG* \[[@B31], [@B42]\]. These fusions result in a high-level androgen-dependent expression of ERG \[[@B43]\] eventually leading to an altered expression of more than 1,600 genes in prostate epithelial cells \[[@B44]\]. The significant upregulation of PNUTS in cancers having a *TMPRSS2:ER*G fusion demonstrates that PNUTS is either directly or indirectly impacted by ERG expression. Possible explanations for this relationship include the known interaction of PNUTS with PTEN \[[@B10]\]. ERG expression suppresses the transcription of PTEN \[[@B45]\]. The significant association between androgen receptor and PNUTS expression fits well with earlier reports demonstrating interactions between the PNUTS target PP1 and the androgen receptor.

Next to *TMPRSS2:ERG* fusions, genomic deletions at various chromosomal loci represent the most prevalent recurrent genetic alterations in prostate cancer where specific mutations of cancer genes are rare \[[@B46]\] \[[@B47]\] \[[@B31]\] \[[@B48]\]. Most chromosomal deletions either preferentially occur in ERG-negative (5q, 6q, 13q, and 18q) or in ERG-positive (3p, 8p *PTEN* (*10q23*), 12q, 16, and 17p) cancers. To exclude false statistical associations due to the link of both PNUTS expression and deletions to the ERG status, this analysis was also done for ERG-positive and ERG-negative cancers. That elevated PNUTS expression which was significantly associated with the majority of the analyzed deletions in ERG-negative cancers highlights that elevated PNUTS levels are either a cause or a consequence of genomic instability in prostate cancer cells. Given the pivotal interaction of PNUTS with PP1, an impact of PNUTS on the level of genomic stability appears plausible. Overexpression of NIPP1, another interaction partner of PP1, was earlier shown to limit a cell\'s capacity to repair DNA double-strand breaks \[[@B49]\]. Upregulation of PNUTS was most striking in cancers with PTEN and 12p13 deletions. In the case of PTEN, this may fit to the known functional interaction of both proteins. PNUTS binds directly to the PTEN protein and inactivates it through controlling its phosphatase activity. Knockdown of PNUTS in cell lines from prostate and other cancers resulted in apoptosis and growth arrest in a PTEN-dependent manner \[[@B10]\]. It could be hypothesized that high-level PNUTS expression may result in a particularly strong growth advantage in cancers with already reduced PTEN activity due to heterozygous deletion. However, this notion is not supported by the conspicuous lack of prognostic impact of PNUTS expression in 967 PTEN-deleted cancers. The tight relationship of elevated PNUTS expression and 12p13 deletions may pinpoint towards another relevant functional interaction. For example, ING4 maps to 12p13 and it is a tumor suppressor protein that contains a PHD-finger, which is a common motif in proteins involved in chromatin remodeling \[[@B50], [@B51]\]. Similarly, CHD4 is also in this target deleted region and it is also involved in chromatin remodeling \[[@B52], [@B53]\]. The data of this study identify high PNUTS expression as a strong and potentially clinically applicable prognostic marker in prostate cancer. The independent prognostic role of PNUTS expression was even retained if prognostic parameters were included, such as pT and pN stage, that are only available after prostatectomy and which are not known at the moment when therapeutic decisions are taken. That PNUTS expression which showed a prognostic impact in Gleason 3+4 (*p* \< 0.0001) and Gleason 4+3 carcinomas (*p* = 0.0002) demonstrates that these morphologically defined subgroups include cancers with highly variable aggressiveness. We had earlier shown that subdividing Gleason 3+4 and 4+3 cancers according to their percentage of Gleason 4 pattern results in a much finer prediction of tumor progression \[[@B21]\]. The limited prognostic role of PNUTS expression in cancers with comparable quantitative Gleason grade underscores the potential prognostic power of an optimized morphological prostate cancer assessment. This also demonstrates how difficult it is for a prognostic molecular marker to compete with an optimized assessment of morphological prostate cancer features. It is of note, however, that there is not only a need for better predictors of PCA aggressiveness than the existing ones but also for more reproducible parameters. The Gleason grade, for example, suffers from an interobserver variability in the range of 40% \[[@B54], [@B55]\]. This issue is not fully solved by a quantitative Gleason grading approach. We thus expect that molecular analysis including multiple different features will in the future improve prognosis assessment.

5. Conclusions {#sec5}
==============

In summary, the results of our study demonstrate that upregulation of PNUTS is tightly linked to aggressive tumor behavior and poor prognosis in prostate cancer. Measuring PNUTS expression either alone or in combination with other prognostic markers might have clinical utility in prostate cancer.
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Supplementary Table S1: PNUTS staining and prostate cancer phenotype in ERG-negative cancers. Supplementary Table S2: PNUTS staining and prostate cancer phenotype in ERG-positive cancers. Supplementary Table S3: multivariate Cox regression analysis including established prognostic parameters and the PNUTS expression in all prostate cancers, the ERG-*negative* and ERG-*positive* subsets. Supplementary Fig. S1: association between PNUTS immunostaining and common chromosomal deletions in (a) all cancer, (b) ERG-negative cancers, and (c) ERG-positive cancers. Supplementary Fig. S2: prognostic impact of PNUTS defined by the Gleason score. (a) Impact of PNUTS expression as compared to the classical Gleason score categories. Impact of expression as compared to the quantitative Gleason score categories defined by subsets of cancers with (b) ≤5% Gleason 4 patterns, (c) 6-10% Gleason 4 patterns, (d) 11-20% Gleason 4 patterns, (e) 21-30% Gleason 4 patterns, (f) 31-49% Gleason 4 patterns, (g) 50-60% Gleason 4 patterns, and (h) ≥61% Gleason 4 patterns.

###### 

Click here for additional data file.

![Examples of PNUTS staining: (a) comparison of PNUTS staining in (1) normal and (2) cancerous prostate glands of the same TMA spot. Cancer spots with (b) lack of staining and (c) weak, (d) moderate, and (e) strong staining.](DM2020-7050146.001){#fig1}

![Association between PNUTS expression and biochemical recurrence after prostatectomy.](DM2020-7050146.002){#fig2}

![PNUTS staining and ERG status (IHC/FISH).](DM2020-7050146.003){#fig3}

![PNUTS staining and androgen receptor expression.](DM2020-7050146.004){#fig4}

###### 

Pathological and clinical data of the arrayed prostate cancers.

                                 No. of patients (%)   
  ------------------------------ --------------------- -------------
  *Follow-up*                    14,464                3,612 (25%)
  Mean/median (month)            56/48                 ---
  *Age* (*y*)                                          
  ≤50                            433                   66 (15%)
  51-59                          4,341                 839 (19%)
  60-69                          9,977                 2,073 (21%)
  ≥70                            2,936                 634 (22%)
  *Pretreatment PSA* (*ng/ml*)                         
  \<4                            2,225                 313 (14%)
  4-10                           10,520                1,696 (16%)
  10-20                          3,662                 1,043 (29%)
  \>20                           1,231                 545 (44%)
  *pT stage* (*AJCC 2002*)                             
  pT2                            11,518                1,212 (11%)
  pT3a                           3,842                 1,121 (29%)
  pT3b                           2,233                 1,213 (54%)
  pT4                            85                    63 (74%)
  *Gleason grade*                                      
  ≤3+3                           3,570                 264 (7%)
  3+4                            9,336                 1,436 (15%)
  3+4 tertiary 5                 1,697                 165 (10%)
  4+3                            2,903                 683 (24%)
  4+3 tertiary 5                 1,187                 487 (41%)
  ≥4+4                           999                   531 (53%)
  *pN stage*                                           
  pN0                            10,636                2,243 (21%)
  pN+                            1,255                 700 (56%)
  *Surgical margin*                                    
  Negative                       14,297                2,307 (16%)
  Positive                       3,388                 1,304 (39%)

^∗^Numbers do not always add up to 17,747 in different categories because of cases with missing data. AJCC: American Joint Committee on Cancer.

###### 

PNUTS expression and cancer phenotype.

  Parameter                            *N*      PNUTS expression (%)   *p*             
  ------------------------------------ -------- ---------------------- ----- ---- ---- ----------
  *All cancers*                        12,235   21                     34    35   10   
  *Tumor stage*                                                                        \<0.0001
  pT2                                  7,895    25                     36    32   8    
  pT3a                                 2,707    17                     30    38   14   
  pT3b-pT4                             1,590    12                     31    42   14   
  *Gleason grade*                                                                      \<0.0001
  ≤3+3                                 2,379    34                     31    28   7    
  3+4                                  6,559    20                     36    34   10   
  3+4 tertiary 5                       549      15                     37    40   8    
  4+3                                  1,168    14                     31    40   15   
  4+3 tertiary 5                       867      10                     34    44   13   
  ≥4+4                                 619      15                     29    42   14   
  *Quantitative Gleason grade*                                                         \<0.0001
  ≤3+3                                 2,379    34                     31    28   7    
  3+4 ≤5%                              1,682    24                     39    30   7    
  3+4 6-10%                            1,639    22                     36    33   9    
  3+4 11-20%                           1,466    18                     35    35   12   
  3+4 21-30%                           737      16                     33    39   13   
  3+4 31-49%                           570      17                     36    37   10   
  3+4 tertiary 5                       549      15                     37    40   8    
  4+3 50-60%                           501      14                     34    39   14   
  4+3 tertiary 5                       867      10                     34    44   13   
  4+3 61-100%                          521      15                     29    40   16   
  ≥4+4                                 542      15                     31    41   13   
  *Lymph node metastasis*                                                              \<0.0001
  N0                                   7,347    18                     34    37   11   
  N+                                   856      10                     31    44   15   
  *Preoperative PSA level* (*ng/ml*)                                                   0.0001
  \<4                                  1,469    20                     36    33   11   
  4-10                                 7,293    21                     35    35   9    
  10-20                                2,546    22                     33    35   10   
  \>20                                 854      22                     28    37   14   
  *Surgical margin*                                                                    \<0.0001
  Negative                             9,771    22                     35    34   9    
  Positive                             2,423    18                     30    39   13   

###### 

PNUTS staining correlates with Ki67 labeling index.

  Gleason          PNUTS      *N*           Ki67LI (mean ± SEM)   *p*
  ---------------- ---------- ------------- --------------------- ----------
  All              Negative   1,181         1.74 ± 0.07           \<0.0001
  Weak             1,695      2.71 ± 0.06                         
  Moderate         1,831      3.02 ± 0.06                         
  Strong           598        3.82 ± 0.10                         
  ≤3+3             Negative   386           1.46 ± 0.10           \<0.0001
  Weak             349        2.42 ± 0.11                         
  Moderate         345        2.43 ± 0.11                         
  Strong           92         3.41 ± 0.21                         
  3+4              Negative   622           1.69 ± 0.09           \<0.0001
  Weak             968        2.54 ± 0.07                         
  Moderate         1,065      2.86 ± 0.07                         
  Strong           336        3.55 ± 0.12                         
  3+4 tertiary 5   Negative   32            1.75 ± 0.42           0.0019
  Weak             82         3.35 ± 0.26                         
  Moderate         70         3.71 ± 0.29                         
  Strong           14         2.93 ± 0.64                         
  4+3              Negative   78            2.29 ± 0.36           0.0009
  Weak             150        3.41 ± 0.26                         
  Moderate         183        3.36 ± 0.24                         
  Strong           80         4.38 ± 0.36                         
  4+3 tertiary 5   Negative   30            3.37 ± 0.70           0.1913
  Weak             90         3.34 ± 0.40                         
  Moderate         105        4.35 ± 0.37                         
  Strong           42         4.45 ± 0.59                         
  ≥4+4             Negative   33            3.24 ± 0.80           0.0528
  Weak             56         3.66 ± 0.62                         
  Moderate         61         4.97 ± 0.59                         
  Strong           33         5.88 ± 0.80                         

###### 

Cox proportional hazards for PSA recurrence-free survival after prostatectomy of established preoperative prognostic parameter and PNUTS expression.

  Variable                                       *N*      Univariable analysis    Multivariable analysis (*N* = 4,392)
  ------------------------ --------------------- -------- ----------------------- --------------------------------------
  Gleason grade biopsy     ≥4+4 vs. ≤3+3         12,172   5.91 (5.33-6.55)^∗∗∗^   3.75 (3.13-4.49)^∗∗∗^
  cT stage                 T2c vs. T1c           14,404   2.15 (1.72-2.65)^∗∗∗^   2.00 (1.46-2.74)^∗∗∗^
  Preoperative PSA level   ≥20 vs. \<4           14,611   5.06 (4.41-5.81)^∗∗∗^   3.69 (2.80-4.86)^∗∗∗^
  PTEN                     Deletion vs. normal   6,236    2.10 (1.89-2.33)^∗∗∗^   1.44 (1.26-1.65)^∗∗∗^
  PNUTS expression         Strong vs. negative   10,029   2.21 (1.93-2.53)^∗∗∗^   1.61 (1.30-2.01)^∗∗∗^
   ERG-negative subset     Strong vs. negative   4,342    2.70 (2.17-3.36)^∗∗∗^   ---
   ERG-positive subset     Strong vs. negative   3,811    2.16 (1.67-2.83)^∗∗∗^   ---

Confidence interval (95%) in brackets; asterisks indicate significance level: ^∗^*p* ≤ 0.05, ^∗∗^*p* ≤ 0.001, and ^∗∗∗^*p* ≤ 0.0001.
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